ホームOPL • ASX
add
Opyl Ltd
市場ニュース
財務情報
損益計算書
収益
純利益
(AUD) | 2024年6月info | 前年比変化率 |
---|---|---|
収益 | 7.70万 | -53.11% |
営業費用 | 42.14万 | 55.20% |
純利益 | -92.70万 | -67.65% |
純利益率 | -1204.33 | -257.51% |
1 株当たりの収益 | — | — |
EBITDA | -90.91万 | -66.48% |
実効税率 | — | — |
貸借対照表
総資産
負債総額
(AUD) | 2024年6月info | 前年比変化率 |
---|---|---|
現金および短期投資 | 37.46万 | -17.27% |
総資産 | 41.16万 | -41.99% |
負債総額 | 50.18万 | -54.93% |
純資産 | -9.02万 | — |
発行済み株式 | 2.22億 | — |
帳簿価格 | ∞ | — |
総資産利益率 | -556.44% | — |
資本利益率 | 2,540.24% | — |
キャッシュ フロー
現金の純増減額
(AUD) | 2024年6月info | 前年比変化率 |
---|---|---|
純利益 | -92.70万 | -67.65% |
営業キャッシュ フロー | -73.83万 | -58.54% |
投資キャッシュ フロー | -8856.00 | -7,807.14% |
財務キャッシュ フロー | 64.21万 | 72.83% |
現金の純増減額 | -10.50万 | -11.42% |
フリー キャッシュ フロー | -17.16万 | 42.93% |
概要
Opyl is a Melbourne-based company listed on the Australian Securities Exchange that applies artificial intelligence to improving clinical trial efficiencies. The company has two key platforms: Opin a global clinical trial recruitment platform and service as well as TrialKey a Saas software as a service platform that predicts and designs optimized clinical trial protocols, reducing the risk of failure and improving a return on investment in new and emerging medicines, devices, and diagnostics..
Opyl is a rebrand and strategic realignment from a former company known as ShareRoot, a US-based martech platform that secured rights to user-generated content on social media, predominantly used by big brands that collaborated with influencers.
Before going public in 2016, ShareRoot had previously participated in 500 Startups batch 8 and raised a round of angel investing.
ShareRoot was rebranded to Opyl in 2020 to work on technology to support the health and life sciences sector. Wikipedia
設立
2013
ウェブサイト
従業員数
3